search
Back to results

Monitoring Neonatal Resuscitation Trial (MONITOR)

Primary Purpose

Resuscitation, Neonatal Prematurity, Positive-Pressure Respiration

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
New Life Box Respiratory Function Monitor
Sponsored by
University of Pennsylvania
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Resuscitation focused on measuring Resuscitation, Neonatal Prematurity, Positive-Pressure Ventilation, Respiratory Function Monitor

Eligibility Criteria

24 Weeks - 28 Weeks (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Gestational age (GA) 24 - 27 6/7 weeks at birth, by best obstetrical
  • Receive positive pressure ventilation during delivery room resuscitation

Exclusion Criteria:

  • Known major anomalies including that may affect measured cardiorespiratory parameters: congenital diaphragmatic hernia, trachea-oesophageal fistula, cyanotic heart disease, pulmonary hypoplasia
  • RFM not available during resuscitation

Sites / Locations

  • Hospital of the University of Pennsylvania

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

RFM visible

RFM masked

Arm Description

During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants can see the information displayed on the New Life Box Respiratory Function Monitor screen.

During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants cannot see the information displayed on the New Life Box Respiratory Function Monitor screen. Though the display is masked, data is collected in the background.

Outcomes

Primary Outcome Measures

Percentage of Positive-Pressure Ventilation Inflations Between 4 - 8 Mls/kg
To test the hypothesis that observing the data and waveforms displayed on an RFM during the provision of PPV to preterm infants (24-27 6/7 weeks gestation) after birth will increase the percentage of inflations performed with a predefined VTe "safe range" of 4 - 8 mls/kg.

Secondary Outcome Measures

Percentage of Oxygen Saturation (SpO2) in the First 5 Minutes of Life
Median percentage of oxygen saturation (SpO2) captured on the Respiratory Function Monitor in the first 5 minutes of life
Heart Rate in the First 10 Minutes of Life
Median Heart rate captured on the Respiratory Function Monitor between 3 and10 minutes of life
Percentage of Time With Mask Leak During PPV Ventilation
Percentage of time with significant mask leak (defined as > 60%) during the duration of PPV ventilation per infant in the first 15 minutes of resuscitation.
Percentage of PPV Inflations With Airway Obstruction
Percentage of PPV inflations with airway obstruction in the first 15 minutes of resuscitation. Airway obstruction is defined as Vte <1 mL/kg, with minimal mask leak (<25%) during an inflation and flattening of the flow waves.
Percentage of PPV Inflations With Inadequate Tidal Volume
Percentage of PPV inflations with inadequate tidal volume defined as Vte <4 ml/kg in the first 15 minutes of resuscitation.
Percentage of Oxygen Saturation (SpO2) in the First 10 Minutes of Life
Median percentage of Oxygen saturation (SpO2) captured on the Respiratory Function Monitor between 3 and 10 minutes of life
Fraction of Inspired Oxygen (FiO2) Provided in the First 10 Minutes of Life
Median fraction of inspired oxygen (FiO2) provided to the infant between 3 and 10 minutes of life
Total Duration With FiO2 of 100% Delivered in the First 10 Minutes of Life
Total duration of time where FiO2 of 100% is delivered to the patient in first 10 minutes of life will be calculated taking into consideration birth weight, tidal volume, respiratory rate, FiO2 and timing of stabilization.
Number of Participants Receiving Endotracheal Intubation in the Delivery Room
Number of Participants receiving Endotracheal Intubation in the delivery room from time of birth to admission to NICU
Number of Participants Requiring Inotropes for Circulatory Support
Number of participants requiring inotropes for circulatory support in the Neonatal Intensive Care Unit in the first 3 days after birth
Number of Participants With Pneumothorax
Number of participants with pneumothorax in the first 72 hours after birth reported by a radiologist masked to the intervention
Number of Participants With Pulmonary Interstitial Emphysema
Number of participants with Pulmonary Interstitial Emphysema in the first 72 hours after birth reported by a radiologist masked to the intervention
Number of Participants With Abnormal Cranial Ultrasound Findings
Number of participants with abnormal cranial ultrasound findings (i) all intraventricular hemorrhage, (ii) severe - ie. Papile grade III and IV intraventricular hemorrhage, (iii) cystic periventricular leukomalacia through study completion, an average of 4 months
Duration of Endotracheal Ventilation
Duration of endotracheal (ET) ventilation days through study completion, an average of 4 months
Duration of Non-invasive Ventilation
Duration of non-invasive ventilation, days through study completion, an average of 4 months
Duration of Supplemental Oxygen Therapy
Duration of supplemental oxygen therapy days through study completion, an average of 4 months
Total Duration of Assisted Ventilation
Total duration of assisted ventilation (ET, CPAP) in hours through study completion, an average of 4 months
Number of Participants With a Diagnosis of Bronchopulmonary Dysplasia
Number of participants with a diagnosis of bronchopulmonary dysplasia (BPD) at 36 weeks corrected gestational age defined as the need for supplementary oxygen and/or any form respiratory support
Neonatal Mortality
Neonatal mortality from the time of birth until hospital discharge or 44 weeks corrected gestational age, whichever occurred first
Composite Outcome of Death or BPD
Composite outcome of death or BPD. BPD assessed at corrected gestational age of 36 weeks; death assessed from time of birth until discharge, up to 44 weeks corrected gestational age
Number of Participants With Retinopathy of Prematurity Requiring Treatment
Number of participants with Retinopathy of prematurity requiring treatment before hospital discharge, an average of 4 months
Number of Participants With a Diagnosis of Necrotizing Enterocolitis
Number of participants with a diagnosis of Necrotizing enterocolitis grade 2 or more before hospital discharge, an average of 4 months
Number of Participants Requiring Fluid Boluses for Circulatory Support
Number of participants requiring fluid boluses for circulatory support in the Neonatal Intensive Care Unit within the first 3 days of life
Number of Participants With Endotracheal Intubation in the NICU
Number of Participants with Endotracheal Intubation in the NICU in the first 24 hours of life
Neonatal Mortality in the Delivery Room
Neonatal Mortality in the delivery room from time of birth until transfer to NICU

Full Information

First Posted
August 15, 2017
Last Updated
November 18, 2021
Sponsor
University of Pennsylvania
Collaborators
Leiden University Medical Center, Royal Women's Hospital in Melbourne, Australia, Maternal & Children's University Hospital, Valencia, Spain, Vittore Buzzi Children's Hospital, Karolinska University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03256578
Brief Title
Monitoring Neonatal Resuscitation Trial
Acronym
MONITOR
Official Title
A Multi-center Randomized Controlled Trial of Respiratory Function Monitoring During Stabilization of Preterm Infants at Birth
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
February 20, 2017 (Actual)
Primary Completion Date
May 17, 2019 (Actual)
Study Completion Date
September 20, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Pennsylvania
Collaborators
Leiden University Medical Center, Royal Women's Hospital in Melbourne, Australia, Maternal & Children's University Hospital, Valencia, Spain, Vittore Buzzi Children's Hospital, Karolinska University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a randomized trial to determine if a visible respiratory function monitor (RFM) displaying realtime measurements of delivered inflations improves clinical providers ability to perform positive pressure ventilation (PPV) within a pre-defined target tidal volume in preterm infants after birth.
Detailed Description
Recently, it has been demonstrated that the use of a respiratory function monitor (RFM) can guide PPV in the DR.(Wood, Schmolzer) In this study, the New Life Box, (Advanced Life Diagnostics, Weener, Germany) a neonatal Respiratory Monitor (RFM), will be used to measure and calculate inflation pressures, flow, and tidal volumes in all enrolled infants. The New Life Box uses a small variable orifice anemometer to measure gas flow in and out of a face-mask or endotracheal tube. This signal is automatically integrated to provide inspired (Vti) and expired (Vte) tidal volume. The difference equals the leak from the facemask or endotracheal tube. Complete airway obstruction occurs when no flow of gas into or away from the infant is seen during a positive pressure inflation. The RFM can also calculate and measure respiratory rate and minute volume, inflations and spontaneous inspirations, and all ventilation pressures. Using customized software heart rate, oxygen saturation and expired carbon dioxide can be integrated into the RFM. The NewLife Box monitor presents graphical information for pressure, flow, and volume. In addition, the monitor displays numeric data for pressure (PIP and PEEP), tidal volume (Vti, Vte), flow, respiratory rate and percent leak. The monitor integrates and displays physiologic data streaming from the patient (heart rate and oxygen saturation) as well as FiO2 from an oxygen analyzer in the inspiratory limb of the respiratory circuit. If enabled, the monitor can incorporate video captured from an external camera. The video serves as a helpful aid in the interpretation of the events during the RFM waveform recordings. The use of an RFM in the DR has the potential to improve neonatal respiratory support and reduce lung injury. The primary objective of this study is to test the hypothesis that observing the data and waveforms displayed on an RFM during the provision of PPV to preterm infants (24-27 6/7 weeks gestation) after birth will increase the proportion of inflations performed with a predefined VTe "safe range" of 4 - 8 mls/kg.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Resuscitation, Neonatal Prematurity, Positive-Pressure Respiration
Keywords
Resuscitation, Neonatal Prematurity, Positive-Pressure Ventilation, Respiratory Function Monitor

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Eligible infants are either randomized to the intervention, where the clinical team will be able to directly observe the monitor or randomized to the RFM-masked display arm, where they will only see a black screen.
Masking
Outcomes Assessor
Masking Description
The waveform data and videos captured during the study intervention will be centralized to Leiden University Medical Center. The team at Leiden University Medical Center assessing the outcomes will be will be blinded to the randomization allocation of the infant.
Allocation
Randomized
Enrollment
288 (Actual)

8. Arms, Groups, and Interventions

Arm Title
RFM visible
Arm Type
Experimental
Arm Description
During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants can see the information displayed on the New Life Box Respiratory Function Monitor screen.
Arm Title
RFM masked
Arm Type
No Intervention
Arm Description
During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants cannot see the information displayed on the New Life Box Respiratory Function Monitor screen. Though the display is masked, data is collected in the background.
Intervention Type
Device
Intervention Name(s)
New Life Box Respiratory Function Monitor
Intervention Description
The intervention is the use of a visible New Life Box Respiratory Function Monitor display in infants born between 24 and 27 6/7 weeks gestation receiving PPV for resuscitation after birth.
Primary Outcome Measure Information:
Title
Percentage of Positive-Pressure Ventilation Inflations Between 4 - 8 Mls/kg
Description
To test the hypothesis that observing the data and waveforms displayed on an RFM during the provision of PPV to preterm infants (24-27 6/7 weeks gestation) after birth will increase the percentage of inflations performed with a predefined VTe "safe range" of 4 - 8 mls/kg.
Time Frame
the first 15 minutes of resuscitation
Secondary Outcome Measure Information:
Title
Percentage of Oxygen Saturation (SpO2) in the First 5 Minutes of Life
Description
Median percentage of oxygen saturation (SpO2) captured on the Respiratory Function Monitor in the first 5 minutes of life
Time Frame
approximately first 5 minutes of life
Title
Heart Rate in the First 10 Minutes of Life
Description
Median Heart rate captured on the Respiratory Function Monitor between 3 and10 minutes of life
Time Frame
between 3 and 10 minutes of life
Title
Percentage of Time With Mask Leak During PPV Ventilation
Description
Percentage of time with significant mask leak (defined as > 60%) during the duration of PPV ventilation per infant in the first 15 minutes of resuscitation.
Time Frame
approximately first 15 minutes of resuscitation
Title
Percentage of PPV Inflations With Airway Obstruction
Description
Percentage of PPV inflations with airway obstruction in the first 15 minutes of resuscitation. Airway obstruction is defined as Vte <1 mL/kg, with minimal mask leak (<25%) during an inflation and flattening of the flow waves.
Time Frame
approximately first 15 minutes of resuscitation
Title
Percentage of PPV Inflations With Inadequate Tidal Volume
Description
Percentage of PPV inflations with inadequate tidal volume defined as Vte <4 ml/kg in the first 15 minutes of resuscitation.
Time Frame
approximately first 15 minutes of resuscitation
Title
Percentage of Oxygen Saturation (SpO2) in the First 10 Minutes of Life
Description
Median percentage of Oxygen saturation (SpO2) captured on the Respiratory Function Monitor between 3 and 10 minutes of life
Time Frame
Between 3 and 10 minutes of life
Title
Fraction of Inspired Oxygen (FiO2) Provided in the First 10 Minutes of Life
Description
Median fraction of inspired oxygen (FiO2) provided to the infant between 3 and 10 minutes of life
Time Frame
between 3 and 10 minutes of life
Title
Total Duration With FiO2 of 100% Delivered in the First 10 Minutes of Life
Description
Total duration of time where FiO2 of 100% is delivered to the patient in first 10 minutes of life will be calculated taking into consideration birth weight, tidal volume, respiratory rate, FiO2 and timing of stabilization.
Time Frame
approximately first 10 minutes of life
Title
Number of Participants Receiving Endotracheal Intubation in the Delivery Room
Description
Number of Participants receiving Endotracheal Intubation in the delivery room from time of birth to admission to NICU
Time Frame
from time of birth to admission to NICU
Title
Number of Participants Requiring Inotropes for Circulatory Support
Description
Number of participants requiring inotropes for circulatory support in the Neonatal Intensive Care Unit in the first 3 days after birth
Time Frame
within the first 3 days after birth
Title
Number of Participants With Pneumothorax
Description
Number of participants with pneumothorax in the first 72 hours after birth reported by a radiologist masked to the intervention
Time Frame
in the first 72 hours after birth
Title
Number of Participants With Pulmonary Interstitial Emphysema
Description
Number of participants with Pulmonary Interstitial Emphysema in the first 72 hours after birth reported by a radiologist masked to the intervention
Time Frame
in the first 72 hours of life
Title
Number of Participants With Abnormal Cranial Ultrasound Findings
Description
Number of participants with abnormal cranial ultrasound findings (i) all intraventricular hemorrhage, (ii) severe - ie. Papile grade III and IV intraventricular hemorrhage, (iii) cystic periventricular leukomalacia through study completion, an average of 4 months
Time Frame
through study completion, an average of 4 months
Title
Duration of Endotracheal Ventilation
Description
Duration of endotracheal (ET) ventilation days through study completion, an average of 4 months
Time Frame
days through study completion, an average of 4 months
Title
Duration of Non-invasive Ventilation
Description
Duration of non-invasive ventilation, days through study completion, an average of 4 months
Time Frame
days through study completion, an average of 4 months
Title
Duration of Supplemental Oxygen Therapy
Description
Duration of supplemental oxygen therapy days through study completion, an average of 4 months
Time Frame
days through study completion, an average of 4 months
Title
Total Duration of Assisted Ventilation
Description
Total duration of assisted ventilation (ET, CPAP) in hours through study completion, an average of 4 months
Time Frame
through study completion, an average of 4 months
Title
Number of Participants With a Diagnosis of Bronchopulmonary Dysplasia
Description
Number of participants with a diagnosis of bronchopulmonary dysplasia (BPD) at 36 weeks corrected gestational age defined as the need for supplementary oxygen and/or any form respiratory support
Time Frame
at 36 weeks corrected gestational age
Title
Neonatal Mortality
Description
Neonatal mortality from the time of birth until hospital discharge or 44 weeks corrected gestational age, whichever occurred first
Time Frame
from time of birth until discharge from hospital, up to 44 weeks corrected gestational age
Title
Composite Outcome of Death or BPD
Description
Composite outcome of death or BPD. BPD assessed at corrected gestational age of 36 weeks; death assessed from time of birth until discharge, up to 44 weeks corrected gestational age
Time Frame
BPD assessed at corrected gestational age of 36 weeks; death assessed from the time of birth until hospital discharge or 44 weeks corrected gestational age, whichever occurred first
Title
Number of Participants With Retinopathy of Prematurity Requiring Treatment
Description
Number of participants with Retinopathy of prematurity requiring treatment before hospital discharge, an average of 4 months
Time Frame
before hospital discharge, an average of 4 months
Title
Number of Participants With a Diagnosis of Necrotizing Enterocolitis
Description
Number of participants with a diagnosis of Necrotizing enterocolitis grade 2 or more before hospital discharge, an average of 4 months
Time Frame
before hospital discharge, an average of 4 months
Title
Number of Participants Requiring Fluid Boluses for Circulatory Support
Description
Number of participants requiring fluid boluses for circulatory support in the Neonatal Intensive Care Unit within the first 3 days of life
Time Frame
within the first 3 days of life
Title
Number of Participants With Endotracheal Intubation in the NICU
Description
Number of Participants with Endotracheal Intubation in the NICU in the first 24 hours of life
Time Frame
in the first 24 hours of life
Title
Neonatal Mortality in the Delivery Room
Description
Neonatal Mortality in the delivery room from time of birth until transfer to NICU
Time Frame
from time of birth until transfer to NICU

10. Eligibility

Sex
All
Minimum Age & Unit of Time
24 Weeks
Maximum Age & Unit of Time
28 Weeks
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Gestational age (GA) 24 - 27 6/7 weeks at birth, by best obstetrical Receive positive pressure ventilation during delivery room resuscitation Exclusion Criteria: Known major anomalies including that may affect measured cardiorespiratory parameters: congenital diaphragmatic hernia, trachea-oesophageal fistula, cyanotic heart disease, pulmonary hypoplasia RFM not available during resuscitation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Arjan te Pas, MD
Organizational Affiliation
Leiden University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital of the University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
18192329
Citation
Wood FE, Morley CJ, Dawson JA, Davis PG. A respiratory function monitor improves mask ventilation. Arch Dis Child Fetal Neonatal Ed. 2008 Sep;93(5):F380-1. doi: 10.1136/adc.2007.120097. Epub 2008 Jan 11.
Results Reference
background
PubMed Identifier
19776023
Citation
Schmolzer GM, Kamlin OC, Dawson JA, te Pas AB, Morley CJ, Davis PG. Respiratory monitoring of neonatal resuscitation. Arch Dis Child Fetal Neonatal Ed. 2010 Jul;95(4):F295-303. doi: 10.1136/adc.2009.165878. Epub 2009 Sep 22.
Results Reference
background
PubMed Identifier
34302924
Citation
van Zanten HA, Kuypers KLAM, van Zwet EW, van Vonderen JJ, Kamlin COF, Springer L, Lista G, Cavigioli F, Vento M, Nunez-Ramiro A, Oberthuer A, Kribs A, Kuester H, Horn S, Weinberg DD, Foglia EE, Morley CJ, Davis PG, Te Pas AB. A multi-centre randomised controlled trial of respiratory function monitoring during stabilisation of very preterm infants at birth. Resuscitation. 2021 Oct;167:317-325. doi: 10.1016/j.resuscitation.2021.07.012. Epub 2021 Jul 22.
Results Reference
derived

Learn more about this trial

Monitoring Neonatal Resuscitation Trial

We'll reach out to this number within 24 hrs